EverGlade Insights Blog

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease

At EverGlade, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we're excited to inform you about a new Request for Applications...

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings...

A Comprehensive Guide to ARPA-H Funding: Process, Financial, and Technical Requirements

The Advanced Research Projects Agency for Health (ARPA-H) stands as a beacon for those within the biomedical and health sectors, propelling transformative research initiatives and breakthroughs. The pursuit of funding from ARPA-H is a monumental...

EverGlade Lands ModeX Therapeutics Up to $168 Million in BARDA Funding

EverGlade, a national consulting firm, has helped ModeX Therapeutics successfully secure up to $168 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to develop novel multispecific antibodies against...

ARPA-H Solicits Proposals For REACT Program

Advanced Research Projects Agency (ARPA-H) Solicits Proposals for Resilient Extended Automatic Cell Therapies (REACT) Program The Advanced Research Projects Agency for Health (ARPA-H) is actively seeking innovative proposals through the Resilient Extended Automatic Cell Therapies...

Effective Post-Award Management of a BARDA Contract

The Biomedical Advanced Research and Development Authority (BARDA) plays a pivotal role in the United States’ preparedness for public health emergencies. BARDA contracts support the development, procurement, and deployment of medical countermeasures critical for safeguarding...